Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most ...
Under terms of the deal, Novo Nordisk will get an exclusive license to use NanoVation’s lipid nanoparticle technology for two lead programs, and NanoVation will receive up to US$600 million in ...
On Wednesday, Cantor Fitzgerald reaffirmed its positive stance on Novo Nordisk (NYSE:NVO), maintaining an Overweight rating and a price target of $160.00. The reaffirmation came as Novo Nordisk ...
Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...
Novo Nordisk A/S (NVO) has turned into one of the most valuable pharma companies in the world thanks to its success with weight loss drug Wegovy. But growth has recently slowed down, and the ...
Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Novo Nordisk NVO in the last three months. The table below offers a condensed view of their ...
Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...
Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may ...
(RTTNews) - Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy ...
Danmarks mest værdifulde virksomhed Novo Nordisk har i årevis ført en omfattende PR- og lobbykampagne for at gøre fedme til en kronisk sygdom. Det vurderer en række eksperter i DR’s nye podcastserie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback